Anticancer drug efficacy or depending on tumor type and variation
February 05, 2018 Source: Science and Technology Daily
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];A clinical trial published online by Nature in the UK recently showed that the efficacy of anticancer drugs targeting specific variants depends on the type of tumor tissue and the exact nature of the mutation. This new discovery brings a new dawn to the development of today's difficult individualized cancer treatments, while also emphasizing the value of the epoch-making cancer treatments of the “Basket trialsâ€.
In many cancers, researchers have observed different variations in the HER2 and HER3 genes, some of which result in overexpression of the HER2 protein, which causes cancer, but most of the mutations are not characterized.
The US Memorial Sloan-Kettering Cancer Center research team tested the drug natalin in 141 patients with different cancers (breast, lung, bladder and colorectal), as well as the HER2 and HER3 genes. The efficacy of a range of different variants. Linatinib is a new drug from American Biotechnology Corporation for the treatment of adult patients with early HER2-positive breast cancer. In July 2017, it became the first “enhanced adjuvant therapy†approved by the US Food and Drug Administration (FDA). Medication.
In the latest test, the researchers found that the drug blocks the activity of HER-like proteins, and the response to treatment depends on the variation and tissue type, and is limited to cancers with HER2 gene variants. This means that clinical trials driven by molecular targets can be used to better understand the effects of genetic variation.
Researchers say that the current path to developing personalized cancer treatments is hampered because the clinical and biological importance of most genetic variants is unknown, and new research can help change this situation and bring us unpredictable preclinical models. New insights.
This test also emphasizes the value of the “basket testâ€, which focuses more on the type of variation than on cancerous tissue, allowing patients with different tumors with the same target to be treated with the same targeted drug. Tumors are treated with the same disease, which is considered to be of epoch-making significance for cancer treatment. (Reporter Zhang Mengran)
Editor-in-chief
February 4th is the 19th World Cancer Day. The statistics in the 2017 China Cancer Registry Annual Report are shocking: China has 4.29 million new cases of cancer diagnosed each year, with a total of 2.81 million deaths, which means that about 8.2 people are diagnosed with cancer on average every minute. At the same time, about 5.4 people were killed by cancer. To cope with cancer, the advancement of modern medicine is naturally an indispensable means. But for healthy people, the best anti-cancer weapon is to develop healthy habits, because prevention is the best treatment.
Polyacrylamide is a kind of high molecular polymer. It is widely used for industry like water treatment, paper, oil, coal, mine, textile, construction, etc.
Polyacrylamide Gel Electrophoresis,Anionic Polyacrylamide,Polyacrylamide Crystals,Polyacrylamide Polymer,Sds Polyacrylamide Gel Electrophoresis
Shandong Tiancheng Chemical Co., Ltd. , https://www.tianchengchemical.com